Normal view MARC view ISBD view

Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. [Review]

MedStar author(s):

Citation: Drug design, development & therapy. 11:923-937, 2017PMID: 28356718Institution: MedStar Health Research InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Diabetes Mellitus, Type 2/dt [Drug Therapy] | *Dipeptidyl-Peptidase IV Inhibitors/tu [Therapeutic Use] | *Hypoglycemic Agents/tu [Therapeutic Use] | *Sodium-Glucose Transporter 2/ai [Antagonists & Inhibitors] | Dipeptidyl-Peptidase IV Inhibitors/pd [Pharmacology] | Humans | Hypoglycemic Agents/pd [Pharmacology] | Sodium-Glucose Transporter 2/me [Metabolism]Year: 2017 ISSN:

1177-8881

Name of journal: Drug design, development and therapyAbstract: Type 2 diabetes mellitus (T2DM) is a progressive and multifactorial cardiometabolic disorder. Almost half of adults with diabetes fail to achieve their recommended glucose control target. This has prompted some clinicians to advocate the use of more intensive initial therapy, including the use of combination therapy to target multiple physiologic defects in diabetes with the goal of achieving and sustaining glucose control. Numerous options exist for combining the various classes of glucose-lowering agents in the treatment of T2DM. This report reviews the mechanism, rationale, and evidence from clinical trials for combining two of the newer drug classes, namely, dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors, and considers the possible role of such dual therapy in the management of T2DM.All authors: Aroda VR, Yassin SAFiscal year: FY2017Digital Object Identifier:

https://dx.doi.org/10.2147/DDDT.S121899

Date added to catalog: 2017-05-06

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	28356718	Available		28356718

Type 2 diabetes mellitus (T2DM) is a progressive and multifactorial cardiometabolic disorder. Almost half of adults with diabetes fail to achieve their recommended glucose control target. This has prompted some clinicians to advocate the use of more intensive initial therapy, including the use of combination therapy to target multiple physiologic defects in diabetes with the goal of achieving and sustaining glucose control. Numerous options exist for combining the various classes of glucose-lowering agents in the treatment of T2DM. This report reviews the mechanism, rationale, and evidence from clinical trials for combining two of the newer drug classes, namely, dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors, and considers the possible role of such dual therapy in the management of T2DM.

English